Drug Repurposing for Drug Development in Stroke

The development of new treatments for acute stroke has been fraught with costly and spectacularly disappointing failures. Repurposing of drugs already known to be safe provides a lower risk alternative. Investigators are using drug repurposing, in which marketed drugs are exploited for their secondary activity, to pursue agents that have multiple mechanisms of action, including vascular protection. Protecting the ischemic vasculature is likely to promote neuronal recovery and have long‐lasting benefits for patients with stroke. Currently, reperfusion with drugs or devices and acute aspirin therapy are used clinically to reduce disability due to ischemic stroke. In the future, drugs such as statins, angiotensin II receptor blockers, minocycline, and growth factors such as erythropoietin may be used. In fact, vascular protection with the angiotensin II receptor blocker candesartan has already been demonstrated in a clinical trial of acute ischemic stroke.

[1]  Susan C Fagan,et al.  Minocycline and Tissue-Type Plasminogen Activator for Stroke: Assessment of Interaction Potential , 2009, Stroke.

[2]  M. Ginsberg.  Current status of neuroprotection for cerebral ischemia: synoptic overview. , 2009, Stroke.

[3]  R. Conwit,et al.  Neuroprotective agents for clinical trials in ALS , 2006, Neurology.

[4]  Adnan I. Qureshi,et al.  Guidelines for the Early Management of Adults With Ischemic Stroke , 2007 .

[5]  H. Elewa,et al.  Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. , 2009, Stroke.

[6]  D. Hess,et al.  Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection , 2006, Journal of hypertension.

[7]  Bryan L. Roth,et al.  Finding New Tricks For Old Drugs: An Efficient Route For Public-Sector Drug Discovery , 2005, Nature Reviews Drug Discovery.

[8]  Koroshetz Wj,et al.  Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.

[9]  David J Gladstone,et al.  Toward Wisdom From Failure: Lessons From Neuroprotective Stroke Trials and New Therapeutic Directions , 2002, Stroke.

[10]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[11]  P. Fisher,et al.  β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression , 2005, Nature.

[12]  M. Boguski,et al.  Repurposing with a Difference , 2009, Science.

[13]  K. Garber.  Stroke treatment—light at the end of the tunnel? , 2007, Nature Biotechnology.

[14]  D. Liebeskind,et al.  Trends in Acute Ischemic Stroke Trials Through the 20th Century , 2001, Stroke.

[15]  David C. Hess,et al.  Targets for Vascular Protection After Acute Ischemic Stroke , 2004, Stroke.

[16]  Hung-Yi Chen,et al.  Melatonin decreases neurovascular oxidative/nitrosative damage and protects against early increases in the blood–brain barrier permeability after transient focal cerebral ischemia in mice , 2006, Journal of pineal research.

[17]  D. Hess,et al.  Tactics for Vascular Protection After Acute Ischemic Stroke , 2005, Pharmacotherapy.

[18]  Myron D. Ginsberg,et al.  Neuroprotection for ischemic stroke: Past, present and future , 2008, Neuropharmacology.

[19]  W. Burke.  Neuroprotective agents for clinical trials in ALS: systematic assessment. , 2006, Neurology.

[20]  H. Diener,et al.  The ACCESS Study: Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors , 2003, Stroke.

[21]  K. Rhodes,et al.  Extension of the Thrombolytic Time Window With Minocycline in Experimental Stroke , 2008, Stroke.

[22]  J. Medina-Franco,et al.  The prince and the pauper. A tale of anticancer targeted agents , 2008, Molecular Cancer.

[23]  H. Elewa,et al.  Blood pressure lowering after experimental cerebral ischemia provides neurovascular protection , 2007, Journal of hypertension.

[24]  R Abagyan,et al.  Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs , 2007, Proceedings of the National Academy of Sciences.

[25]  E. Bézard,et al.  Neuroprotective agents for clinical trials in Parkinson’s disease: A systematic assessment , 2004, Neurology.

[26]  H. Elewa,et al.  Early Atorvastatin Reduces Hemorrhage after Acute Cerebral Ischemia in Diabetic Rats , 2009, Journal of Pharmacology and Experimental Therapeutics.

[27]  H. Elewa,et al.  Vascular Protection with Candesartan after Experimental Acute Stroke in Hypertensive Rats: A Dose-Response Study , 2008, Journal of Pharmacology and Experimental Therapeutics.